The firm is a single family office based in the Midwest. The firm actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries.
The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more.
The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.
By Rory McCann, Marketing Manager & Conference Producer, LSN
RESI Partnering Week (RPW) returns September 13-17 for five days of match-based partnering, educational workshops, expert panels, innovative pitch sessions, and more!
RPW features a unique model made up of three days of Digital Redefining Early Stage Investments (RESI), followed by two days of targeted partnering and unique content designed specifically for age-tech and AI technology.
Get to know each event to see which are a fit for you! Super early bird rates are available until July 9, so register today to SAVE!
The Redefining Early Stage Investments (RESI) conference series brings together startups with early-stage investors and strategic channel partners to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. RESI is cross-border and cross-domain, connecting start-ups with ten categories of global investors across the silos of drugs, devices, diagnostics, and digital health. RESI caters to both the earliest stage startups, those seeking grants, seed and angel capital, and the early-stage firms who seek seed, series A, and B funding.
Artificial intelligence (AI) is rapidly reshaping the healthcare landscape and redefining what is possible in life science. RESI AI is a digital partnering conference that connects the investors and strategic partners and matches them to companies developing and commercializing AI technology in drugs, devices, diagnostics, and digital health to revolutionize healthcare. RESI AI features investors and entrepreneurs sharing their experiences in early-stage funding and what makes a successful partnership. This two-day digital conference provides the opportunity to meet and learn from experts, build relationships, and advance healthcare through the power of AI.
The aging boomer population contributed $8.3 trillion in economic activity to the 2018 US economy, and that number is projected to triple by 2050. The need for advancements in drugs, devices, diagnostics, and digital health for the treatment of age-related conditions is crucial. RESI Longevity is a new partnering conference focused on conditions related to aging, market challenges, and solutions via early-stage companies and their promising tech and products. RESI Longevity brings fundraising startups together with investors in age-tech innovation to make deals in order that today’s seniors live longer, healthier lives.
Learn more about what to expect at each event and how you can get involved!
1:1 Partnering
The investors attending RESI represent a huge pool of capital, and Life Science Nation (LSN)’s unique partnering system enables fundraising companies find the investors and strategic partners that are a best fit for their technology and stage of development.
Review profiles of other participants.
Schedule one-on-one and/or group meetings.
Build your customized conference schedule, from panels to presentations to partnering meetings
Investor Panels & Workshops
Panels and workshops highlight panelists who can provide their perspective on current trends, as well as valuable advice to fundraising start-ups. From big corporations to angel groups, and from established VCs to family offices, the panelists participating at RESI reflect LSN’s global investor network. Panels will be live-streamed, giving audience members a chance to get their questions answered in real-time.
Innovator’s Pitch Challenge
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Participating companies pay registration and a pitching fee to host their company materials on the Live Agenda and participate in the live pitch session.
Exhibitors and sponsors will be featured on a dedicated page with a virtual exhibitor booth, showcasing their services and the value they can provide. Participating tech hubs can highlight their programs and constituent companies.
By Karen Deyo, Director of Investor Research, Israel BD, LSN
Life Science Nation’s (LSN) most recent Digital Redefining Early Stage Investments (RESI) conference is wrapping up today. Digital RESI June is proof that the digital model has worked and continues to add value to the early-stage fundraising ecosystem. This week’s event featured an exciting lineup of insightful panels with engaged audiences, live pitch sessions with eager and active investor judges, and educational workshops hosted by key industry leaders like the National Institutes of Health (NIH).
The success of Digital RESI is never clearer than when looking at the RESI Partnering Platform. Over the 3 days of the event, 1600+ meetings were booked, with some companies booking as many as 34 meetings. The chart shows the breakdown of the meetings taking place – three quarters of which are investors and companies connecting, either for the first time, or continuing an existing dialog.
Numbers don’t lie, and the Digital RESI conference series continues to prove the importance of a partnering-focused event in moving the needle forward in the early-stage funding ecosystem.
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
You’ve prepped your materials, done your research, messaged potential partners, booked meetings, delivered a pitch, sent your Thank-Yous… Now what? How do you make the most of your time at Digital RESI June after the curtain closes? Life Science Nation (LSN) has designed the Redefining Early Stage Investments (RESI) conference series around the reality of early-stage fundraising in life science. It’s a numbers game. LSN’s model works because it includes regular partnering events built on a match-based strategy, and the products and services fill in the gaps between events.
LSN’s database subscriptions utilize one-on-one interviews with our community, ensuring that the fundraising executive or investor has the latest information at their fingertips, providing a RESI-esque experience between the conferences. LSN databases are designed with the end user in mind and their goals of reaching strategic partners and technology assets that are a fit for their needs. Fundraising executives can find active investors who are a fit for their product and stage of development, and investors can source product pipelines, portfolio assets, licensing opportunities, and so much more.
RESI is a unique experience, and the closest our attendees come is through our database subscriptions. Learn more about how they are enabled to meet your needs and contact a business development representative for a demo!
Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International & MA (USA)
West Coast (USA)
East Coast (USA) & CanadaÂ
Greg Mannix Vice President International Business Development Book a Meeting!
A healthcare-dedicated investment firm founded in 2015 with offices in USA has 4 active investment vehicles that allow them to work with companies across various stages of development including private equity, long/short hedge fund, crossover venture fund, and SPAC.
In terms of early-stage opportunities, the firm allocates a few million dollars as initial investment (at a minimum), amount varying on a deal-by-deal basis, and is capable of investing up to $50M over the company’s lifecycle. The firm is open to North American and European opportunities.
The firm is interested in therapeutics, medical devices, tools, labs/diagnostics, and pharmaceutical services. The firm is opportunistic in terms of subsectors and will consider all things healthcare.
The firm prefers to work with management teams that have entrepreneurial experience. The business must show strong potential, and either be revenue-generating or have visibility to approach positive revenue in the next 12-24 months. The company should be built around strong and distinguishable IP that presents a significant market opportunity.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A large pharmaceutical headquartered in China with more than 40 branches and subsidiaries around the world (including the United States, Japan, Germany, Russia, Spain, India, etc.) has their main business covering chemical and biological medicines, pharmaceutical packaging, and trading.
The investment subsidiary of this pharmaceutical has 200 million RMB assets under management, and is looking for investment and in-licensing opportunities in novel drug research and development. The firm also invests in funds. The firm’s allocation size is decided case by case.
The firm is most interested in companies developing novel drugs in biologics, cell therapy, gene therapy, repurposed drugs, and biosimilars. The firm is interested in distribution rights. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A single family office based in the USA actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries.
The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more.
The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
